SCHEMBL5583949

SCHEMBL5583949

NC(=O)c1nc2nc(Nc3ccc(N4CCOCC4)cc3)ncc2cc1-c1c(Cl)cccc1Cl

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 4/20 0.62
FGFR1 P11362 3/20 0.62
PKMYT1 Q99640 2/20 0.62
SLC2A1 P11166 2/20 0.62
PDGFRB P09619 1/20 0.62
PDGFRA P16234 1/20 0.62
MAPK8 P45983 1/20 0.56
MAPK9 P45984 1/20 0.56
MAPK10 P53779 1/20 0.56
STAT6 P42226 6/20 0.54
JAK2 O60674 1/20 0.53
JAK1 P23458 1/20 0.53
TYK2 P29597 1/20 0.53
JAK3 P52333 1/20 0.53
WEE1 P30291 2/20 0.52
FGFR2 P21802 1/20 0.52
FGFR4 P22455 1/20 0.52
FGFR3 P22607 1/20 0.52
SYK P43405 1/20 0.51
BRD4 O60885 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5583941 0.92 SRC (0.63) SRCFGFR1PKMYT1SLC2A1PDGFRB
SCHEMBL4413320 0.84 IGF1R (0.52) MAPK8MAPK9MAPK10STAT6JAK2
SCHEMBL5583963 0.82 SRC (0.66) SRCFGFR1PKMYT1SLC2A1PDGFRB
SCHEMBL5583797 0.82 SRC (0.62) SRCFGFR1PKMYT1SLC2A1PDGFRB
SCHEMBL5657548 0.79 FGFR1 (0.55) SRCFGFR1PKMYT1SLC2A1PDGFRB
SCHEMBL29508114 0.77 SRC (1.00) SRCFGFR1PKMYT1SLC2A1PDGFRB
SCHEMBL3458816 0.77 SRC (1.00) SRCFGFR1PKMYT1SLC2A1PDGFRB
SCHEMBL3865248 0.76 CCND3 (0.52) SRCFGFR1PKMYT1SLC2A1PDGFRB
SCHEMBL4424151 0.76 IGF1R (0.56) SRCFGFR1PKMYT1SLC2A1PDGFRB
SCHEMBL14573081 0.76 WEE1 (0.56) SRCFGFR1PDGFRBPDGFRAWEE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2007529451-A 2007-10-25 JP claimed
US-7189732-B2 Pyrido[2,3-d]pyrimidine dichloro-phenyl derivatives HOFFMAN-LA ROCHE INC. (US) 2007-03-13 US claimed
EP-1727819-A1 NOVEL DICHLORO-PHENYL-PYRIDO¬2,3-D|PYRIMIDINE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F.HOFFMANN-LA ROCHE AG (CH) 2006-12-06 EP claimed
US-20060014765-A1 Dichloro-phenyl derivatives HOFFMANN-LA ROCHE INC. 2006-01-19 US claimed
WO-2005090344-A1 NOVEL DICHLORO-PHENYL-PYRIDO [2,3-D] PYRIMIDINE DERIVATES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2005-09-29 WO claimed
US-7189732-B2 Pyrido[2,3-d]pyrimidine dichloro-phenyl derivatives HOFFMAN-LA ROCHE INC. (US) 2007-03-13 US disclosed
US-20060014765-A1 Dichloro-phenyl derivatives HOFFMANN-LA ROCHE INC. 2006-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014765-A1 Dichloro-phenyl derivatives SRC, ABL1, LCK SRC 1/4885FGFR1 145/4885PKMYT1 460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.